指南与共识心血管US

根据2016年美国超声心动图学会/欧洲心血管影像协会建议识别舒张功能障碍的评分对肥厚型心肌病患者预后的相关性

Prognostic Relevance of a Score for Identifying Diastolic Dysfunction according to the 2016 American Society of Echocardiography/European Association of Cardiovascular Imaging Recommendations in Patients with Hypertrophic Cardiomyopathy.
指南 / 共识 · J Am Soc Echocardiogr · 2021-12-20

本研究纳入290例肥厚型心肌病患者,按2016年ASE/EACVI建议用四项超声参数(室间隔e'<7 cm/sec、E/e'>15、左房容积指数>34 mL/m2、三尖瓣反流峰值速度>2.8 m/sec)计算评分,以3分为界分组。中位随访9.7年,评分≥3分者HCM相关不良结局发生率显著更高(log-rank P=.010),多因素分析调整后HR=1.92(95%CI 1.05-3.49,P=.033)。

要点

  • 室间隔e'<7 cm/sec、E/e'>15、左房容积指数>34 mL/m2、三尖瓣反流峰值速度>2.8 m/sec各计1分。
  • 评分≥3分者占37.2%,HCM相关不良结局发生率24.1%,高于评分<3分者的13.7%。
  • 评分≥3分是全因组合终点的独立决定因素(调整后HR=1.92,95%CI 1.05-3.49,P=.033)。

核心结论

  • 遵循ASE/EACVI建议识别舒张功能障碍的评分可能与肥厚型心肌病患者的不良结局相关。

研究设计与样本

  • 研究纳入290例肥厚型心肌病患者,采用超声心动图评估四项舒张功能参数并计算评分,以3分为界分组,主要终点为HCM相关不良结局的组合终点。

诊断标准与关键数值

  • 异常截断值:室间隔e'<7 cm/sec、室间隔E/e'>15、左房容积指数>34 mL/m2、三尖瓣反流峰值速度>2.8 m/sec,每项异常计1分,以3分为分组界值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: In hypertrophic cardiomyopathy (HCM), one of the main pathophysiological features is diastolic dysfunction. According to the 2016 American Society of Echocardiography (ASE)/European Association of Cardiovascular Imaging (EACVI) recommendations, diastolic function is assessed with echocardiographic variables. However, the association between the ASE/EACVI recommendations and the outcome in patients with HCM remains unclear. We evaluated the prognostic implications of the ASE/EACVI recommendations in patients with HCM.

METHODS: This study included 290 patients with HCM. We evaluated four variables for identifying diastolic dysfunction using the following abnormal cutoff values: septal e' < 7 cm/sec, septal E/e' ratio > 15, left atrial volume index > 34 mL/m2, and peak tricuspid regurgitation velocity > 2.8 m/sec. A score was developed in which one point was designated for each abnormal echo parameter of diastolic function. We divided patients into two groups with an ASE/EACVI score of 3 as the cutoff value. The primary endpoint was the combination of HCM-related adverse outcomes (combination of sudden death or potentially lethal arrhythmic events, heart failure-related death, and heart failure hospitalization).

RESULTS: The prevalence of an ASE/EACVI score ≥3 was 37.2%. Over a median follow-up of 9.7 (6.9-12.9) years, 26 (24.1%) patients with an ASE/EACVI score ≥3 and 25 (13.7%) patients with an ASE/EACVI score <3 experienced a combination of HCM-related adverse outcomes. Patients with an ASE/EACVI score ≥3 had a significantly higher incidence of the combined endpoint than those with an ASE/EACVI score <3 (log-rank, P = .010). An ASE/EACVI score ≥3 was an independent determinant of the combined endpoint in multivariate analysis (adjusted hazard ratio = 1.92; 95% CI, 1.05-3.49; P = .033).

CONCLUSIONS: The score for identifying diastolic dysfunction by following ASE/EACVI recommendations may be associated with an adverse outcome in patients with HCM.

来源:J Am Soc Echocardiogr,查看原文。版权归原作者所有。

引用

  1. Saito, Minami, Haruki, et al. Prognostic Relevance of a Score for Identifying Diastolic Dysfunction according to the 2016 American Society of Echocardiography/European Association of Cardiovascular Imaging Recommendations in Patients with Hypertrophic Cardiomyopathy. J Am Soc Echocardiogr. 2021. PMID: 34933117. doi:10.1016/j.echo.2021.12.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。